Enibarcimab (Adrecizumab)

About Adrenomed

Adrenomed is a clinical-stage biotech pioneering a precision medicine approach for acute care, specifically targeting septic shock. Its lead asset, enibarcimab, is a first-in-class antibody designed to restore vascular integrity by modulating the vasoprotective peptide adrenomedullin. The company has generated promising Phase II data using a biomarker-guided strategy and has secured FDA Fast Track designation, positioning it to address a critical unmet medical need with a targeted therapeutic. It remains a privately held company backed by venture capital investors.

Therapeutic Areas

Other Septic Shock Drugs